According to the 2017 ELN guidelines (6), a high percentage (74%) of AML experts perform molecular analyses of RUNX1, ASXL1, TP53 genes for a proper definition of the “adverse risk” category. This evidence concerns the gene RUNX1 and acute myeloid leukemia.